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ABSTRACT 
The clinical introduction of Non-invasive Prenatal Testing (NIPT) in the United States in 
2011 significantly impacted the field of prenatal genetic screening. Through molecular analysis 
of cell-free fetal DNA extracted from maternal serum samples, NIPT provides pregnant women 
with their risk to have a child with the most common aneuploidies seen in live born children: 
trisomy 21, 18, 13, and sex chromosome abnormalities. Moreover, the detection rates for the 
conditions screened for by NIPT are higher than those offered by prior prenatal genetic screening 
tests and NIPT poses no additional risk to the fetus unlike prenatal genetic diagnostic testing 
(i.e., chorionic villi sampling and amniocentesis). Clinical utilization of NIPT to screen for fetal 
aneuploidy is rapidly growing; multiple professional organizations have released position 
statements recommending that NIPT be offered to all women as a genetic screening option.  
 With the rapid expansion of NIPT it is important to assess the clinical outcome of this 
emerging technology to inform genetic counseling practices and policy development. This study 
is a retrospective medical records review of data from women who had NIPT through Magee-
Womens Hospital of UPMC’s Center for Medical Genetics and Genomics, a high-risk referral 
center, from January 1, 2014 to December 31, 2016. A total of 2,589 women had non-invasive 
prenatal testing (NIPT) and 95 women (3.67%) from the original cohort who received a positive 
or failed result were included in the analysis. Our results showed that the positive predictive 
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value for trisomy 21 was 100% (95% CI:90.5-100), 66.7% (95% CI:9.4-99.2) for trisomy 18, and 
50% (95% CI: 98.7) for trisomy 13. The NIPT fail rate was 1.62% and concordant with the test 
fail rates published by laboratories and prior studies. Continued analysis of the clinical outcomes 
and utilization of NIPT should be performed in order to provide more accurate genetic 
counseling, inform universal screening practices, and improve prenatal care of pregnancies with 
aneuploidy. This study is relevant to public health because it contributes to current knowledge of 
the clinical outcomes of NIPT to aid healthcare professionals in assessing patients’ risks for fetal 
aneuploidy. 
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1.0  INTRODUCTION 
Fetal aneuploidy is the leading known cause of miscarriage and congenital birth defects 
in the United States1,2. It is estimated that 10-30% of pregnancy losses are due to fetal 
aneuploidy and 0.65% of live born infants have chromosomal abnormalities3,4. Pregnancies with 
chromosome abnormalities pose a significant risk to the mother for miscarriage and 
complications due to miscarriage such as infection and excessive bleeding. Aneuploid fetuses are 
at an increased risk for miscarriage/fetal demise and can exhibit multiple congenital anomalies, 
growth restriction, and other pre- and postnatal complications. The chance for individuals to 
have a child with a chromosome abnormality increases with maternal age5. Women who will be 
age 35 or older at the time of delivery, are classified as advanced maternal age and are 
considered to be at an increased risk to have a child with aneuploidy5,6.  
Prenatal genetic screening tests are designed to aid healthcare professionals in identifying 
pregnant women who are at an increased risk for fetal aneuploidy within the general population. 
Throughout the United States, pregnancy screening for fetal aneuploidy is offered to all pregnant 
women as the standard of care. Early identification of fetuses at an increased risk for 
chromosome abnormalities enables families to diagnose medical conditions affecting the fetus 
prior to birth and make medical management decisions regarding the developing fetuses. 
Medical decision making can include planning of neonatal medical interventions, coordination of 
palliative care services, and/or discussion of pregnancy termination options. Genetic counseling 
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can also be offered to families to provide information with regards to the clinical features and 
prognosis of genetic conditions, and other genetic testing options for the pregnancy, as well as to 
support families in autonomous decision making5,7. 
Prenatal genetic screening tests include ultrasound and analysis of maternal serum 
samples for specific hormone and protein markers. The sensitivities of these screening methods 
are in the range of 69-95% for the detection of trisomies 21, and 18. Diagnostic testing options of 
amniocentesis and chorionic villus sampling offer pregnant women higher sensitivities of 
approximately 99% but these procedures pose a risk of miscarriage of less than 1%8. In 2011, a 
new prenatal screening test known as Non-invasive Prenatal Testing (NIPT) or cell-free fetal 
DNA testing was made commercially available throughout the United States9,10. 
NIPT offers higher detection rates and screens for a broader array of conditions than prior 
prenatal screening options at no additional risk to the fetus10. The American College of 
Obstetricians and Gynecologists (ACOG) in conjunction with the Society for Maternal Fetal 
Medicine (SMFM) have released a committee statement supporting the use of NIPT to screen 
high-risk pregnancies for fetal aneuploidy6,11. NIPT utilizes next generation sequencing to 
analyze maternal serum samples for the presence of fetal DNA in order to determine if there are 
an increased or decreased amounts of chromosomes 13, 18, 21, X and Y. The sensitivity and 
specificity of NIPT to detect trisomies 21, 18, and 13 are approximately 97-99% as reported by 
commercial testing companies12–17. Due to its high accuracy and non-invasive methodology, 
NIPT is becoming increasingly popular as a screening option for high-risk pregnancies18.  
However, studies on the clinical outcomes and accuracy of NIPT have been fairly limited 
to those sponsored by commercial testing companies or clinical centers outside of the United 
States. Furthermore, only a few studies that have analyzed the clinical use of NIPT have included 
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follow-up of NIPT results to determine how frequent a NIPT result is congruent with the birth 
outcome and/or diagnostic testing result19,20. Follow-up of NIPT results can help to determine the 
positive predictive value, true positive rate, false positive rate, false negative rate, and true 
negative rate of NIPT. These types of results can aid genetic counselors and other healthcare 
providers in providing more accurate information about NIPT to their patients considering 
prenatal screening for chromosome conditions and inform healthcare professionals of further 
pregnancy management options that may be indicated by specific NIPT results.   
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2.0  LITERATURE REVIEW 
2.1 ANEUPLOIDY 
Aneuploidy is defined as the presence of abnormal amounts of chromosomes in a cell3,21. 
According to ACOG, aneuploidy embryos accounts for 10-30% of all pregnancies1,22. The most 
common aneuploidies observed in liveborn infants are trisomy 21, trisomy 18, trisomy 13, and 
sex chromosome aneuploidies that include XXY, XYY, XXX, and 45, X3,23. Newborns with 
aneuploidy can experience shortened lifespans, congenital birth defects, failure to thrive, and/or 
intellectual disability21.  
Due to the high proportion of early pregnancy losses associated with fetal aneuploidy, the 
incidence of newborns with chromosomal abnormalities is estimated to be less than 1% (1 in 
150) livebirths6. Approximately 1 in 691 liveborn infants in the United States are diagnosed with 
trisomy 21, a condition also known as Down syndrome23. The incidence of trisomy 18 and 13 is 
estimated to be 1 in 3,762 livebirths and 1 in 7,906 livebirths, respectively23. The incidence of 
sex chromosome aneuploidies can range from about 1 in 400 to 1 in 4000 births depending on 
the exact condition.  
The prevalence of aneuploid pregnancies increases with maternal age6. Women who are 
35 years or older at the time of delivery, are defined as “advanced maternal age” and are 
considered to be at an increased risk for fetal aneuploidy6. A woman’s age-related risk for fetal 
aneuploidy is not influenced by their race or ethnicity however, family history of inherited 
chromosome rearrangements (for example, a balanced translocation), abnormal ultrasound 
findings, a prior pregnancy history and/or positive pregnancy screening results can increase an 
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individual’s baseline risk6. Additional prenatal screening and diagnostic testing in addition to 
alternative medical management plans and services should be offered to individuals who are 
identified to be at an increased for fetal aneuploidy5,6. 
2.2 PRENATAL SCREENING AND DIAGNOSIS FOR GENETIC 
CONDITIONS 
2.2.1 PRENATAL DIAGNOSTIC TESTING 
There are two types of prenatal diagnostic testing currently available: chorionic villus 
sampling (CVS) and amniocentesis24,25. Both of these procedures are invasive requiring 
physicians to extract a sample from the pregnancy to perform genetic analysis24,26,27. Genetic 
analytic methods performed on prenatal tissue samples obtained from amniocentesis and 
chorionic villi include karyotype, fluorescence in-situ hybridization (FISH), and/or targeted 
molecular analysis. Karyotyping of cultured cells is estimated to be 97.5-99.8% accurate, while 
FISH and microarray analysis are estimated to be greater than 99% accurate28. 
The use of amniocentesis has been reported in the medical literature as early as the 
1870s25,26. During the 19th century, amniocentesis was primarily utilized as a means of reducing 
the buildup of amniotic fluid in cases of polyhydramnios26,29. Physicians began to expand their 
use of amniocentesis in the 1930s in order to manage cases of erythroblastosis fetalis, a 
hematological condition that arises when there is an incompatibility between the Rh-status of the 
mother and fetus25. Following the advent of karyotyping, researchers were able to develop a 
method of culturing fetal cells obtained from amniocentesis to create a karyotype by the late 
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1960s26,27,29. Through this technological advancement, physicians were able to identify 
chromosomal abnormalities affecting pregnancies such as Down syndrome, and modify 
women’s pregnancy management in relation to the amniocentesis results.  
By the mid-1970s amniocentesis became the standard procedure for obtaining fetal 
karyotypes27,29. Amniocentesis can be performed for pregnancies that reach at least 15 weeks 
gestation26,29. In addition to karyotype analysis, amniotic fluid samples can be used to assess a 
pregnancy’s risk for open neural tube and abdominal wall defects by measuring alpha-fetoprotein 
(AFP) and acetylcholinesterase (AChE) levels30. 
 Chorionic villus sampling (CVS) is a prenatal diagnostic method that was developed in 
the 1980s to offer patients a diagnostic test that can be safely performed earlier than 
amniocentesis; CVS can be performed at 11-13 weeks of gestation24. There are two approaches 
for sample extraction including transcervical and transabdominal, the method used depends on 
the position of the placenta relative to the fetus8,27,31. The accuracy of karyotyping and 
microarray analysis for samples obtained by CVS is generally over 99%, however in cases of 
suspected placental mosaicism clinicians may recommend amniocentesis and/or additional 
testing to clarify results24.  
 Both CVS and amniocentesis confer a risk for complications leading to a miscarriage or 
preterm labor due to the invasive nature of their sample collection procedures27,29. Multiple 
studies have shown that due to the earlier age of pregnancy during which CVS is performed,  
there is a higher risk of miscarriage associated with CVS when compared to amniocentesis32. 
However, there has been no difference observed in the pregnancy loss rate for transcervical vs. 
transabdominal CVS procedures8,27. While, randomized trials have found the risk for miscarriage 
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after CVS or amniocentesis range from 0.1- 1%, the risk of pregnancy loss for both procedures is 
often lower than in more experienced centers8.  
2.2.2 MATERNAL SERUM SCREENING 
In order to identify pregnancies at an increased risk for fetal aneuploidy and/or congenital 
birth defects without increasing individuals’ risk for complications leading to miscarriage or 
preterm delivery, pregnancy screening tests were developed4,33.  The first type of pregnancy 
screening test developed was ultrasonography34,35. Ultrasound imaging provides clinicians with 
information regarding pregnancy viability, dating, placental location, fetal number and 
anatomical features34. Fetuses with chromosome abnormalities can have distinctive congenital 
anomalies which can be detected by ultrasound34,36. Ultrasound findings commonly observed in 
fetuses with Down syndrome include shortened long bones, absent nasal bones, echogenic 
intracardiac focus, increased nuchal thickness, and choroid plexus cysts37. However, all fetuses 
with chromosome abnormalities will not have congenital abnormalities that can be detected by 
ultrasound35,38,39.  
A detailed anatomical ultrasound can be performed at 18 to 22 weeks of pregnancy to 
assess the fetus’ growth, position, movement, and anatomy34,40. This  analysis confers a higher 
detection risk for common aneuploidies than that offered by standard ultrasounds37,41. 
Approximately, 73% of Down syndrome pregnancies can be detected by ultrasound (when 
performed at 18-20 weeks of pregnancy and by an experienced ultasonographer) and 90% of 
pregnancies with trisomy 18 or trisomy 13 can be detected at this time36,37,41. The false positive 
rate for trisomy 21 detected by ultrasound is about 4%36,41. Ultrasound imaging can also be used 
to detect open neural tube and abdominal wall defects.  
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 Multiple marker screening was developed in the late 1980s to detect pregnancies that are 
at an increased risk for Down syndrome and open neural tube defects42. In the early 1990s, 
researchers discovered that multiple marker screening could also be used to screen for trisomy 
1842. Multiple marker screening computes a risk for a pregnancy to have trisomy 21, trisomy 18, 
and open neural tube defects by measuring the presence of biochemical markers in the maternal 
serum: alpha-fetoprotein (AFP), human gonadotrophin (hCG), unconjugated estriol (uE3) and 
inhibin-A37,43. Multiple marker screening is typically performed at 16- 20 weeks of gestation36. 
The exact number of biochemical markers that are analyzed varies based on the laboratory used, 
typically three (triple screen) or four (quad screen) markers are measured, although a pentascreen 
that analyzes five biochemical markers is also available. The markers measured by quad screens 
are AFP, hCG, uE3 and inhibin- A, while triple screens measure AFP, hCG, and uE335. In 
addition to the precise measurements of these biochemical markers present in the maternal serum 
sample, maternal age, race, weight, diabetic status, pregnancy history, and the gestational age are 
all tabulated to compute a unique risk estimate for the fetus to have Down syndrome, trisomy 18, 
and/or an open neural tube defect35. The detection rate of quad screening is approximately 70-
75% for trisomy 21, 60% for trisomy 18, 80% for spina bifida, and 90% for pregnancies with 
anencephaly (Table 1)35. The false positive rates for multiple marker screening are 
approximately 5% for trisomy 21 and 8% for trisomy 18 (Table 1)37.  
 To increase the detection rate for common aneuploidies, trisomy 21 and trisomy 18, first 
trimester screening (FTS) was developed. First trimester screening can be performed at 11 to 14 
weeks of pregnancy and involves two components, maternal serum screening and ultrasound 
analysis36. Ultrasound imaging is used to obtain a measurement of the fetus’ nuchal translucency. 
The maternal blood sample is analyzed for the presence of pregnancy associated plasma protein 
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A (PAPP-A) and total human chorionic gonadotropin (total hCG). An increased nuchal 
translucency measurement is associated with the presence of chromosomal abnormalities.  
 The detection rate of first trimester screening is 90% for trisomies 18, and 21. The false 
positive rate of first trimester screening is about 5%44. Nuchal translucency alone can also be 
measured as a means of detecting pregnancies with aneuploidy. Measurement of the nuchal 
translucency has a 70% detection rate for Down syndrome44.  
 To continue to improve aneuploidy detection integrated screening was developed. 
Integrated screening combines elements of first trimester screening and second trimester 
screening to quantify a pregnancy’s risk to be affected with Down syndrome. During the first 
trimester, the nuchal translucency, maternal serum PAPP-A and hCG are measured35. Then the 
AFP, uE3, hCG, and inhibin A levels in a maternal serum sample are measured during the 
second trimester. The detection rate for Down syndrome by integrated screening is 94% with a 
5% false positive rate (Table 1)35. Patients are only informed of the combined integrated 
screening result.  
 
Table 1. Comparison of Prenatal Screening Test Detection and False Positive Rates 
Screening Tests for 
Common Trisomies (21, 18, 
13) 
Detection Rate False Positive Rate 
21 18 13 21 18 13 
Anatomic Ultrasound36,37,41 73% 80% 90-100% 4% n/a n/a 
Multiple Marker Screen37 70-75% 60% n/a 5% 8% n/a 
First Trimester Screen37 90% 90% 90% 5% 5% 5% 
Integrated Screen35 94% n/a n/a 5% n/a n/a 
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2.3 NON-INVASIVE PRENATAL TESTING (NIPT) 
Non-invasive Prenatal testing (NIPT), also known as cell-free fetal DNA (cffDNA) can 
detect pregnancies with chromosomal abnormalities including but not limited to trisomies 21, 18, 
13 and Monosomy X. NIPT can be performed in pregnancies that are at least 10 weeks of 
gestation. In order to detect aneuploidies a maternal blood sample is collected and the amount of 
cffDNA contained in the sample is measured; this measurement is referred to as the fetal 
fraction. The cffDNA is analyzed through the massively parallel sequencing or single-nucleotide 
polymorphism (SNP) approach to assess whether or not the pregnancy is at an increased risk for 
a specific aneuploidy. Massively parallel sequencing detects fetal aneuploidy based on the 
representation of specific chromosomes within the sample compared to unaffected, diploid 
pregnancies45. Natera Inc. is the only commercial laboratory in the United State that uses the 
SNP based approach for NIPT12. This method has been validated by multiple research 
studies44,46.  
Evidence suggestive of feto-maternal cell transfer has been reported as early as the 
1960s47. In 1969, scientists karyotyped cultured lymphocytes from 30 pregnant women and 
discovered cells indicative of 46, XY present in 21 samples from the pregnant women48. Of those 
21 women with 46, XY cells detected via karyotype, 19 of them delivered male fetuses and 2 had 
females48. Although additional studies confirmed these findings of  cffDNA circulating in the 
maternal bloodstream throughout pregnancy, a molecular diagnostic technique to precisely 
identify the fetal DNA had yet to be developed. However, in 1996 researchers were able to 
develop a method to detect tumor DNA in the bloodstream of cancer patients48. Drawing upon 
this discovery, scientists began to investigate whether similar mechanisms could be applied to 
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the precise detection and isolation of cffDNA circulating in the maternal bloodstream during 
pregnancy48,49. 
In the following year, researchers were able to accurately detect specific chromosome 
through the analysis of isolated cffDNA from the maternal bloodstream48. Through this initial 
study, maternal blood samples were collected from 43 pregnant women and additional non-
pregnant controls48. Signals from the Y-chromosome were detected in 24 out of the 30 total fetal 
DNA PCR-products of women pregnant with male fetuses48. Y-chromosome signals were not 
detected in the plasma or serum samples of any of the controls or PCR-products generated from 
the cffDNA extracted from women pregnant with female fetuses48. Moreover, this same group of 
researchers determined that 10µL of maternal serum and plasma is sufficient for the accurate 
detection of cffDNA50. 
Through the culmination of these breakthrough discoveries, numerous validation studies, 
and the innovation of Next-Generation sequencing technology NIPT became clinically available 
in the United States in 2011. Following the release of Committee Opinion 545 from ACOG in 
conjunction with SMFM there was a significant uptake in the clinical adoption of NIPT. In their 
position statement ACOG and SMFM supported the use of NIPT to screen high-risk pregnancies 
for fetal aneuploidy, and the utilization of NIPT began to rapidly increase21. “High-risk 
pregnancies” are defined as those in which one or more of the following risk factors were 
present: mother to be 35 years or older at the time of delivery, family history of a child with a 
known trisomy, parent(s) is a balanced Robertsonian translocation carrier, fetus with ultrasound 
findings associated with an increased risk for aneuploidies, or a positive pregnancy screening test 
indicating an increased risk for fetal aneuploidy5,21. NIPT was not recommended for use in low-
risk pregnancies and cases of multiple gestations, as it was not validated in these populations at 
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the time of its clinical release in 20115,9,11,21,51. The American College of Medical Genetics and 
Genomics (ACMG) and ACOG published updated position statements endorsing the clinical use 
of NIPT to detect fetal aneuploidy for all women regardless of age in 20165,6. The sensitivities 
and specificities of the NIPT offered by commercial laboratories is summarized in Table 2 and 
the positive predictive values reported by each lab are reported in Table 3.  
 
Table 2. Comparison of Clinically Available NIPT Sensitivities and Specificities 
 
*T21=trisomy 21, T18= Trisomy 18, T13= Trisomy 13; SCA= sex chromosome aneuploidy; 
sex= XX and XY 
 
 
Table 3. Comparison of Commercially Available NIPT Positive Predictive Values and Test 
Failure Rates 
 
  MaterniT21/ 
InformaSeq15,17 
Verifi16 Harmony14 Panorama12 Qnatal13 
PPV 92.0% 83.5% n/a 85.05% n/a 
Test Failure 
Rate 
n/a 3.8% n/a n/a n/a 
*PPV= positive predictive value; n/a= information not available; the positive predictive values 
presented in this table are overall values for trisomies 21, 18, 13 
 
 
NIPT’s high detection rates for trisomies 21, 13, and 18 in conjunction with its average 
false positive rates of 0.5% are unprecedented by any other pregnancy screening test (Table 2 & 
3). As a result, NIPT has quickly been adopted into widespread clinical use as a prenatal 
screening tool for fetal aneuploidy. ACMG states that clinicians should continue to offer 
Aneuploidy Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
21 99.1% 99.9% 99.2% 99.9% >99.9% >99.0% >99% 100% 99.1% 99.9%
18 98.3% 99.9% 96.3% 99.87% 97.4% >99.0% >96% 100% 99.9% 99.6%
13 98.2% 99.9% 91.0% 99.87% 93.8% >99.0% >99% 100% 91.7% 99.7%
X 95.0% 99.0% n/a n/a n/a n/a >92% 100% n/a n/a
XX 97.6% 99.2% 97.6% 99.2% n/a n/a >99.9% 100% n/a n/a
XY 99.1% 98.9% 99.1% 98.9% n/a n/a >99.9% 100% n/a n/a
SCAs 96.2% 99.7% n/a n/a n/a n/a 100% 100% 96.2% 99.7%
Triploidy n/a n/a n/a n/a n/a n/a >99.9% 100% n/a n/a
MaterniT21/InformaSeq 
(15,17)
Verifi (16) Harmony (14) Panorama (12) Qnatal (13)
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maternal serum AFP testing to women who choose to pursue NIPT for the detection of open 
neural tube defects5. Moreover, NIPT should not be used as a substitution for anatomic 
ultrasound screening5. It is important to recognize that a negative NIPT result does not exclude 
the possibility that a pregnancy may be affected5,21. For positive NIPT results, the positive 
predictive value should be calculated based on the gestational age of the pregnancy at the time of 
NIPT blood-draw, maternal age, and the particular condition indicated in order to interpret the 
result(s)5,15,21,52. In addition, diagnostic testing should be offered to confirm the positive NIPT 
result. 
Patients may also receive a failed or inconclusive NIPT result when they choose to 
undergo screening. The most commonly reported reasons for failed NIPT results are low fetal 
fraction (<4%), maternal obesity, and administrative/technological failures53–55. NIPT results that 
are failed or inconclusive due to unknown reasons are considered to be an increased risk for fetal 
aneuploidy53,56. However, few clinical laboratories publicly report their test failure rates (Table 
3). According to ACOG and ACMG, women who receive failed NIPT results should be offered 
additional follow-up through: repeat maternal serum sample blood draw and cffDNA analysis, 
additional ultrasound and/or biochemical screening, and/or diagnostic testing5,21. 
 In addition to the aneuploidy conditions that NIPT companies initially screened for, most 
have begun to offer screening for microdeletion and duplication syndromes (see Table 4). 
Information regarding the positive predictive values, sensitivity, and specificity for the detection 
of these microdeletion syndromes with respect to each clinical laboratory is limited or not 
provided12–15,52. Presently, Panorama is the only non-invasive prenatal testing company that has 
expanded its services to offer screening for fetal triploidy12.  
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Table 4. Comparison of Expanded NIPT Screening Options 
  Harmony 
14 
InformaSeq 
15 
Materni21 
Plus 
17 
Panorama 
12 
Qnatal 
Advanced 
13 
Verifi Plus 
16 
Extra 
screening 
options 
available 
Yes No Yes No Yes No Yes No Yes No Yes No 
22q 
(DiGeorge 
syndrome) 
●  ●  ●  ●  ●  ●  
15q deletion 
(Prader-
Willi/ 
Angelman 
syndromes) 
 ● ●  ●  ●  ●  ●  
11q 
(Jacobsen 
syndrome) 
 ● ●  ●   ● ●   ● 
8q (Langer- 
Giedion 
syndrome) 
 ● ●  ●   ● ●   ● 
5p (Criu-du-
chat 
syndrome) 
 ● ●  ●  ●  ●  ●  
4p (Wolf-
Hirschhorn 
syndrome) 
 ● ●  ●   ● ●  ●  
1p36 
deletion 
syndrome 
 ● ●  ●  ●  ●  ●  
Trisomy 16  ● ●  ●   ●  ● ●  
Trisomy 22  ● ●  ●   ●  ● ●  
Triploidy  ●  ●  ● ●   ●  ● 
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2.4 CLINICAL STUDIES ON NIPT PERFORMANCE 
 Following the commercial launch of NIPT in the United States, multiple validation 
studies were performed. In a blinded research study conducted in 2012, Bianchi et al. massively 
parallel sequenced 534 maternal serum samples obtained from pregnant women enrolled in the 
MELISSA study and undergoing prenatal diagnostic testing at 60 clinical testing centers across 
the United States57. Through massive parallel sequencing, Bianchi et al. were able to detect 
trisomy 21 with 100% sensitivity, trisomy 18 with 97.2% sensitivity, and trisomy13 with 78.6%  
sensitivity57. “Unclassified results” were obtained for 2.8% of participants and 10 false negative 
results were obtained, with sex chromosome aneuploidies comprising the majority of false 
negative results57. Meta-analysis of clinical validation studies have found similar results52,58. The 
pooled sensitivity for trisomy 21 was 99.3% (95% CI 98.9% to 99.6%), 97.4% (95.8% to 98.4%) 
for trisomy 18, and 97.4% (86.1% to 99.6%) for trisomy 1358. Another meta-analysis calculated 
a positive predictive value of 88.6% (95% CI 83.0–93.1) for Monosomy X and 93.8% (95% CI 
85.9–98.7) for all sex chromosome abnormalities excluding Monosomy X59. 
 Several clinical studies of NIPT outcomes have reported decreased detection rates for sex 
chromosome abnormalities19,20. A study conducted by Petersen et al. performed cytogenetic 
analysis on  712 maternal serum samples that received an abnormal NIPT result19. The positive 
predictive value for Monosomy X was 27%, while the positive predictive value for Klinefelter 
syndrome (XXY) was approximately 85%19.  
 Adverse pregnancy outcomes and fetal aneuploidy have been associated with failed and 
inconclusive NIPT results53,54. Some risk factors that predispose individuals to receive a failed 
NIPT result have been identified. Multiple studies have shown that maternal use of 
anticoagulants during pregnancy, maternal metastatic malignancies, and maternal weight 
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exceeding 270 pounds all increase an individual’s risk to receive a failed NIPT result54,57,60,61. 
The average test failure rate reported by clinical sites and meta-analysis is approximately 1%, 
however test failure rates as high as 6% within a cohort have been reported19,20,54,58,59. More 
research is need to elucidate the biological mechanisms and risk factors that contribute to NIPT 
failure. 
2.5 FUTURE DIRECTIONS FOR NIPT 
 Only five years after NIPT entered the clinical market, Sequenom became the first 
clinical testing company in the United States to launch a genome wide non-invasive prenatal test 
62. Entitled, MaterniT Genome, this screening test can be performed as “early as nine weeks 
gestation” through a maternal blood draw62. MaterniT Genome reports information regarding the 
fetus’ risk for common trisomies (13,18,21), sex chromosome aneuploidies, seven 
microdeletions  (Table 4), and “clinically relevant” microdeletions or duplications at least 7 Mb 
in size on every chromosome throughout the genome62. Globally, clinical testing companies have 
also began to investigate the use of NIPT to detect monogenic disorders63,64.  
 However, ACOG strongly cautions against the use of NIPT for the detection of 
microdeletion disorders6. Although ACMG does not discourage the use of NIPT microdeletion 
panels they assert that extensive pretest counseling and/or genetic counseling should be provided 
to patients if they choose to have this screening5. No professional organizations have 
recommended the use of NIPT to screen for triploidy or genome-wide NIPT analysis6,9,51,65,66. 
With the rapid evolution and expansion of NIPT subsequent information on its clinical 
performance is needed in order for clinicians and genetic counselors to provide patients with 
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adequate information about the test. The false positive rates, positive predictive values, detection 
rates, and test failure rates are crucial measures to assess the accuracy and clinical validity of 
expanded NIPT options. Presently, few studies independent of commercial laboratory 
sponsorship have been published regarding the clinical use/experience of genetic testing centers 
with NIPT. 
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3.0 MANUSCRIPT 
3.1 BACKGROUND 
3.1.1 ANEUPLOIDY 
Aneuploidy is defined as the presence of abnormal amounts of chromosomes in a cell3. 
According to the American College of Obstetricians and Gynecologists (ACOG), aneuploidy 
embryos accounts for 10-30% of all pregnancies3,4. The most common cause is 
nondisjunction3,39,67. Due to the high proportion of early pregnancy losses associated with fetuses 
with aneuploidy, the incidence of newborns with chromosomal abnormalities is estimated to be 
less than 1% (1 in 150) livebirths6.  
The most common aneuploidies observed in live born infants are trisomy 21, trisomy 18, 
trisomy 13, and sex chromosome aneuploidies that include XXY, XYY, XXX, and 45, X6,23,65,67. 
Approximately 1 in 691 live born infants in the United States are diagnosed with trisomy 21, a 
condition also known as Down syndrome23. The incidence of trisomy 18 and 13 is estimated to 
be 1 in 3,762 livebirths and 1 in 7,906 livebirths, respectively23. The incidence of sex 
chromosome aneuploidies ranges from 1 in 400 to 1 in 4000 based on the exact condition 
specified23.  
There several are risk factors known to increase an individual’s chance to have a child 
with aneuploidies. One risk factor is advanced maternal age, as women age their chance to have 
a child with aneuploidy increases due to the fact that more errors in nondisjunction occur in 
oocytes as maternal age increases3,67. “Advanced maternal age” is defined as women who will be 
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35 years or older at the estimated time of delivery4–6. A woman’s age-related risk is not 
influenced by her race or ethnicity3,68. Balanced translocation carriers are also at an increased 
risk for fetal aneuploidy4,5,11,51. Prenatal screening and diagnostic testing to detect fetal 
aneuploidy should be offered to individuals who are at an increased risk for fetal aneuploidy6.   
3.1.2 PRENATAL SCREENING AND DIAGNOSTIC TESTING  
 Prenatal screening and diagnostic testing in the United States began in the 1970s1,69. 
While diagnostic testing such as amniocentesis and chorionic villi sampling can identify fetal 
aneuploidy with high accuracy, pregnancy screening tests determine the risk for a fetus to be 
affected. If a woman is at an increased risk for a condition based on her screening test results, 
then she can choose to pursue diagnostic testing to verify the screening test results. 
  The first pregnancy screening test developed was ultrasonography. Fetuses with 
aneuploidy can display distinctive anatomical features such as choroid plexus cysts and 
shortened long bones, which can be detected by prenatal ultrasound37. However, not all affected 
fetus will be identified by ultrasound34,37. The presence of anatomical features suggestive of 
chromosome aneuploidy are referred to as soft-markers34,38. A detailed anatomical ultrasound 
can be performed at 18 to 22 weeks of pregnancy to thoroughly assess the fetus’ growth, 
position, movement, and anatomical features for pregnancies diagnosed or suspected of fetal 
aneuploidy37,38,44 . In general, 73% of Down syndrome pregnancies can be detected by 
ultrasound (at 18-20 weeks gestation) and 90% of pregnancies with trisomy 18 or trisomy 13 can 
be detected41,44. The false positive rate for trisomy 21 detected by ultrasound is approximately 
4%36,37,41.  
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To continue to improve prenatal detection for common aneuploidies and reduce the false 
positive rate, maternal serum screenings tests were developed. The first type of maternal serum 
screening test developed was multiple marker screening. Multiple marker screening measures the 
levels of: alpha-fetoprotein (AFP), human gonadotrophin (hCG), unconjugated estriol (uE3) 
and/or inhibin-A in maternal serum samples drawn at 16-20 weeks gestation43. Today, multiple 
forms of multiple marker screening exist: the triple screen, quad screen and pentascreen.  The 
test varies based on the number of biochemical analytes that are measured in maternal serum 
samples. The detection rates are summarized in Table 1.  
  Subsequent prenatal genetic screening tests were developed following the advent of 
multiple marker screening. First trimester screening utilizes a measurement of the fetus’ nuchal 
translucency in conjunction with maternal serum levels of pregnancy associated plasma protein 
(PAPP-A) and total human chorionic gonadotrophin (total hCG) to determine each pregnancy’s  
risk to have a child with trisomy 21 or 1840. This test can be performed at 11-14 weeks of 
gestation40. The detection rate of first trimester screening is 90% for trisomies 18 and 21, the 
false positive rate is roughly 5% (Table 1)40,70. 
  Integrated screening is comprised of two stages, a maternal serum draw is initially done 
at 10-13 weeks of pregnancy and the nuchal translucency of the fetus is measured71. Then a 
second maternal serum draw is performed from 15-21 weeks gestation71. The results obtained 
from the analyses conducted on the maternal serum samples are combined to calculate a final 
risk estimate for trisomy 2171. The detection rate for Down Syndrome by integrated screening is 
94% with a 5% false positive rate35. Patients are only informed of the combined result. The 
detection rate for Down Syndrome by integrated screening is 94% with a 5% false positive 
rate(Table 1)35. Integrated screening detects about 90% of pregnancies with trisomy 1835. 
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Table 1. Comparison of Prenatal Screening Test Detection and False Positive Rates 
Screening Tests for 
Common Trisomies (21, 18, 
13) 
Detection Rate False Positive Rate 
21 18 13 21 18 13 
Anatomic Ultrasound36,37,41 73% 80% 90-100% 4% n/a n/a 
Multiple Marker Screen37 70-75% 60% n/a 5% 8% n/a 
First Trimester Screen37 90% 90% 90% 5% 5% 5% 
Integrated Screen35 94% 90% n/a 5% n/a n/a 
 
There are two prenatal diagnostic tests, amniocentesis and chorionic villus sampling 
(CVS). CVS can be performed at 11-13 weeks gestation to collect a sample of chorionic villi for 
diagnostic testing24,27,32. Amniocentesis can be performed any time after 15 weeks of pregnancy. 
A sample of the amniotic fluid that surrounds the developing fetus is collected and cultured for 
cytogenetic analysis25,32. Both amniocentesis and CVS have an associated risk of complications 
that could lead to miscarriage or preterm delivery and is reported at approximately 1/1000 in 
experienced centers27,32. The accuracy for detection of aneuploidy for both of these tests is nearly 
100%24.  
3.1.3 NON-INVASIVE PRENATAL TESTING (NIPT) 
 Non-invasive Prenatal testing (NIPT), also known as cell-free fetal DNA, can detect 
pregnancies with chromosomal abnormalities through next-generation sequencing of maternal 
serum samples. NIPT can be performed any time after at least 10 weeks, and 0 days of 
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gestation14,50. The risk for fetal aneuploidy is determined by NIPT through massively parallel 
sequencing or the single nucleotide polymorphism approach, depending on the laboratory 
used12,13,15,16,62,72. The sensitivities and specificities of NIPT reported by each commercial testing 
laboratory are listed in Table 2. Multiple professional organizations have released opinion 
statements endorsing the use of NIPT5,9,51,65,66. ACOG and the American College of Medical 
Genetics and Genomics (ACMG) have even amended their original position statements of 
restricting the use of NIPT to high-risk pregnancies to advocating that it should be discussed as 
an option for all women regardless of risk5,6,11,65.  
 Since its release to the U.S. market in 2011, the number of conditions screened for by 
NIPT continues to rapidly expand. Several testing companies have begun to offer expanded 
NIPT options that screen for common trisomies (trisomy 16 and 22) and microdeletion 
syndromes such as Prader-Willi/Angelman Syndrome, DiGeorge Syndrome, and others12–17. In 
addition one laboratory (Natera) is screening for triploidy, and Integrated Genetics now offers a 
“genome-wide NIPT12,62. ACOG does not recommend the clinical use of NIPT to screen for 
common microdeletions and ACMG specifies that clinical correlation and extensive patient 
counseling is needed prior to ordering microdeletion testing6.  
 
Table 2. Comparison of Clinically Available NIPT Sensitivities and Specificities 
 
Aneuploidy Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
21 99.1% 99.9% 99.2% 99.9% >99.9% >99.0% >99% 100% 99.1% 99.9%
18 98.3% 99.9% 96.3% 99.87% 97.4% >99.0% >96% 100% 99.9% 99.6%
13 98.2% 99.9% 91.0% 99.87% 93.8% >99.0% >99% 100% 91.7% 99.7%
X 95.0% 99.0% n/a n/a n/a n/a >92% 100% n/a n/a
XX 97.6% 99.2% 97.6% 99.2% n/a n/a >99.9% 100% n/a n/a
XY 99.1% 98.9% 99.1% 98.9% n/a n/a >99.9% 100% n/a n/a
SCAs 96.2% 99.7% n/a n/a n/a n/a 100% 100% 96.2% 99.7%
Triploidy n/a n/a n/a n/a n/a n/a >99.9% 100% n/a n/a
MaterniT21/InformaSeq 
(15,17)
Verifi (16) Harmony (14) Panorama (12) Qnatal (13)
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3.1.4 CLINICAL STUDIES ON NIPT PERFORMANCE 
 In a blinded study conducted in 2012, over 2000 maternal serum samples from pregnant 
women undergoing diagnostic procedures at 60 clinical centers across the United States were 
collected and massively parallel sequenced to assess the detection rate of NIPT68. Massively 
parallel sequencing was performed on all of the samples and then compared to their cytogenetic 
results. Massively parallel sequencing of the maternal serum samples was able to correctly 
identify trisomies 21, 18, and 13 in addition to sex chromosome aneuploidies in the 532 serum 
samples that indicated an increased risk for fetal aneuploidy10. No false positives within this 
sample were observed, however there were 10 false negative results10. The largest number of 
false negative results were seen amongst the samples with sex chromosome aneuploidies10.  
 Decreased detection rates for sex chromosome aneuploidies by NIPT have been reported 
in several other studies. In Petersen et al.’s study that analyzed 712 maternal serum samples that 
received abnormal NIPT results and had diagnostic testing results, the positive predictive value 
for Monosomy X within their cohort was 27%, while the positive predictive value for Klinefelter 
syndrome (XXY) was approximately 85%19. A meta-analysis of NIPT validation studies 
including the study previously mentioned identified a positive predictive value of 88.6% (95% 
CI 83.0–93.1) for Monosomy X and 93.8% (95% CI 85.9–98.7) for all sex chromosome 
abnormalities excluding Monosomy X59.  
 Failed NIPT results have been associated with an increased risk for adverse pregnancy 
outcomes and fetal aneuploidy. Some of the factors that contribute to NIPT failure have been 
discovered. Maternal use of anticoagulants during pregnancy, maternal metastatic malignancies, 
and maternal weight exceeding 270 pounds have all been determined to increase risk for a failed 
NIPT result54,57,60,61. Test failure rates of less than 2% have been reported for all of the clinical 
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validation and meta-analysis research for NIPT that have been performed thus far19,20,54,58,59. 
Further research is need to elucidate the biological mechanisms that underlie NIPT failure.  
With the rapid evolution and expansion of NIPT, further research on its clinical 
performance is needed in order for clinicians and genetic counselors to provide patients with 
adequate information about the test. The false positive rates, positive predictive values, detection 
rates, test and failure rates are crucial measures to assess the accuracy and clinical validity of 
expanded NIPT options. Few studies independent of commercial laboratory sponsorship have 
been published regarding the clinical experience of genetic testing centers with NIPT at this 
time. The aim of this study is to qualitatively and quantitatively assess the clinical experience of 
one genetic testing referral center, in order to gather data to assess clinical outcomes of NIPT.  
The following were the specific aims of the study: 
1. To identify women who have received NIPT results through Magee-Womens Hospital 
from January 1, 2014- December 31, 2016.  
2. To classify these women as positive, negative, or failed based on their NIPT result using 
the hospital’s secured Materni21 database, cytogenetic records, and medical records. 
3. To determine if any further prenatal or postnatal testing was done on the fetuses of women 
who received a positive or failed NIPT result. The medical records of these patients were 
reviewed but no direct patient contact was done.  
4. To perform statistical analysis of the data collected.  
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3.2 METHODS 
3.2.1 PARTICIPANTS 
Participants were identified utilizing the NIPT results database (entitled MaterniT21) 
maintained by the Center for Medical Genetics and Genomics at Magee-Womens Hospital of 
UPMC. Participants had NIPT ordered through the Center for Medical Genetics and Genomics at 
Magee-Womens Hospital of UPMC between January 1, 2014 and December 31, 2016 as listed in 
the NIPT results database. If an initial failed NIPT result was obtained, then women were offered 
to repeat the test at no additional cost, to repeat the test with the same or an alternate clinical 
laboratory, or to pursue other prenatal screening or diagnostic testing. Women who received non-
invasive prenatal testing through Magee-Womens Hospital of UPMC’s Center for Medical 
Genetics and Genomics but were not documented in the MaterniT21 database were excluded 
from this study. Moreover, only participants who had testing during the previously specified time 
period and received a failed or positive screening result for trisomies 21, 18, and/or 13, were 
included. A total of 95 women listed in the NIPT results database met those criteria and were 
subsequently selected for analysis.  
3.2.2 PROCEDURES 
Prior to the initiation of this study, (PRO17100348) approval by the Institutional Review 
Board of the University of Pittsburgh was obtained (Appendix A). The majority of participants 
included in this study had non-invasive prenatal testing due to an increased risk for fetal 
aneuploidy based on age (≥35 years old at time of delivery), pregnancy screening results, and/or 
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ultrasound findings. No patient contact was involved in this study. A waiver of informed consent 
and HIPAA authorization to access patients’ medical records and genetic testing results were 
obtained (Appendix A). After the waivers were obtained, the data were gathered through review 
of patients’ medical records and compiled into a password protected database at Magee-Womens 
Hospital of UPMC.  
Collected data included genetic tests ordered as the standard of care, follow up prenatal 
and postnatal studies/testing, ultrasound reports, in-patient visit summaries, and obstetrician 
office visit notes. In addition, maternal height, weight, race, medication use, diagnoses, age at 
delivery, and family history of genetic conditions or birth defects were obtained from medical 
records. Descriptions of infants’ dysmorphic features and/or birth defects as documented on their 
respective delivery summaries were included in analysis. NICU progress notes and in-patient 
discharge summaries were analyzed for infants who did not have a dysmorphology exam 
completed on their delivery summaries. Genetic counseling notes, physician letters, and iGene- a 
patient record database for genetic testing results- were examined in the absence of genetic 
testing and/or ultrasound reports to confirm testing results and ultrasound findings documented 
in patients’ obstetrician office visit summaries and progress notes. 
Fetal demises that occurred at 20 weeks gestation or earlier were classified as 
spontaneous abortions, while demises that occurred after 20 weeks and 6 days, as well as 
stillbirths were classified as intrauterine fetal demises. The selective reduction of multiple 
gestation pregnancies was categorized as a terminated abortion. Birth outcomes of fetuses were 
obtained from ultrasound reports, emergency room visit summaries, and delivery summaries. 
Postnatal follow-up of newborns was tracked through their first year of life. 
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Only medications that participants were reported as taking during their pregnancy were 
included in this study. Maternal tobacco, alcohol and/or illicit substance use during pregnancy 
were also categorized as maternal medication exposures. Maternal conditions/diagnoses were 
defined as medical conditions that participants were diagnosed with during their pregnancy, 
including mental health disorders and chronic diseases. 
All NIPT ordered at Magee-Womens’ Hospital of UPMC from 2014 to 2016 was sent to 
one of five genetic testing companies: Integrated Genetics, Illumina Inc, Quest Diagnostics, 
Ariosa Diagnostics, or Natera, Inc. All of these companies utilized a Clinical Laboratory 
Improvement Act (CLIA)-certified laboratory to perform their non-invasive prenatal testing. 
With the exception of Natera, Inc, massively parallel sequencing is used to detect fetal 
aneuploidy at the other laboratories. Natera, Inc employs a single nucleotide polymorphism 
(SNP)-based approach to analyze NIPT samples. Maternal peripheral blood samples were drawn 
at the Magee-Womens Hospital Outpatient Laboratory, packaged, and then sent to a clinical 
testing company. 
3.2.3 CYTOGENETIC METHODS 
Diagnostic testing was performed at the Pittsburgh Cytogenetics Laboratory within 
Magee-Womens Hospital of UPMC for patients who received abnormal NIPT results-- positive 
and failed results. The Pittsburgh Cytogenetics Laboratory is CLIA- certified and located within 
Magee-Womens’ Hospital of UPMC. For FISH analysis the AneuVysion DNA Probe was used 
to detect suspected chromosome 13, 18, 21, X, and/or Y aneuploidy. FISH analysis was routinely 
performed in conjunction with chromosomal microarray and karyotype analysis. Karyotyped 
samples were G-banded at approximately 5-10 Mb resolution and at least 10 metaphase cells or 
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clones were counted for each sample when available. If indicated, additional metaphase cells 
were studied for further analysis. Agilent’s SurePrint G3 CGH+SNP microarrays (4x180K ISCA 
design) platform was used for chromosomal microarray analysis by the Pittsburgh Cytogenetic 
Laboratory during the 2014-2016-time period. Due to technical limitations, balanced 
chromosomal rearrangements, DNA base pair mutations, low level mosaicism (<20%), balanced 
insertions, and unbalanced gains in non-covered regions of the genome cannot be detected by 
SNP or CGH arrays. Sample types submitted for cytogenetic analysis included peripheral blood, 
chorionic villi, amniotic fluid, cord blood, and products of conception.   
3.2.4 DATA ANALYSIS 
Participants were categorized by their NIPT results. Positive results were classified as 
increased risk for trisomy 21, 18, or 13 based on NIPT reports. Fetuses who were positive for a 
sex chromosome aneuploidy in addition to trisomy 21, 18, or 13 were classified based on the 
presence of trisomy 21, 18, or 13. NIPT results that were not able to be reported due to 
insufficient fetal fraction, unacceptable sample quality, or inconclusive were categorized as 
failed.  
Quantitative data analysis was performed using the Stata ® statistical software to determine 
the positive predictive value and false positive valve for each trisomy in addition to the overall 
NIPT failure rate. True positive results were defined as participants who received a positive 
NIPT result (for trisomy 21, 18, and/or 13) and who had follow-up diagnostic chromosome 
analysis either prenatal or postnatal that confirmed the presence of the predicted trisomy. “‘True 
positive results’”- also included cases of aneuploidy due to chromosome translocations and/or 
mosaicism. False positive results were classified as participants whose diagnostic testing results 
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were discordant with their predicted NIPT results. Participants who did not pursue diagnostic 
testing were excluded from this analysis.  
Additional quantitative data analysis was used to compare lab performance and evaluate 
relationships between other variables collected in this study. In order to assess statistical 
difference in the accuracy of NIPT results reported by each laboratory, Fisher’s exact test was 
performed. Linear regressions and Pearson’s correlation coefficient were calculated to determine 
whether or not a statistically significant relationship exists between any of the additional 
variables collected in this study.  
3.3 RESULTS 
3.3.1 PARTICIPANT DEMOGRAPHICS 
A total of 2,589 women had non-invasive prenatal testing (NIPT) through Magee-Womens 
Hospital’s Center for Genetics and Genomics from January 1, 2014 to December 31, 2016. Of 
those tested, 95 women (3.67%) received a positive or failed initial NIPT result and were 
included in analysis (Table 5). Only one participant had two separate pregnancies during the 
time period of the study; for both pregnancies she chose to have an NIPT and received failed 
results. Thereby a total of 95 participants and 96 separate pregnancies were included in our 
cohort. The majority of the participants were Caucasian. All other participants were of African 
American descent, Asian descent, and one participant selected ‘other’ indicating Moroccan 
descent (Table 5). The average age of our cohort was 35.4 years, with the youngest participant 
being 16 years old and the oldest being 45 years old at the time of testing (Table 5). The average 
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BMI of participants was 30.3. Four women had dichorionic and diamniotic twins, while all other 
pregnancies were single gestations. A total of 100 fetuses were included in this study. 
 
Table 5. Participant Demographics 
 
Race Total (n=95) 
Caucasian 75 
African American 8 
Asian 11 
Hispanic 0 
Other 1 
Maternal Age Years 
Average Age 35.40 
St. Dev. Age 5.88 
Min Age 16 
Max Age 45 
Number of 
gestations Total (n=100) 
Singleton 92 
Diamniotic/ 
dichorionic twins 4 
Maternal BMI  
Average 30.3 ± 8.2 
Minimum 17.9 
Maximum 59.9 
 
3.3.2 NIPT RESULTS 
Figure 1 depicts the clinical indications that were reported for NIPT use within this 
cohort. The majority of the participants (n=95, 55%) had NIPT solely due to advanced maternal 
age (Figure 1). The second most common reason for NIPT was due to joint clinical indications 
that included advanced maternal age (AMA), abnormal ultrasound findings (US), and increased 
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risk for fetal aneuploidy by multiple marker screening (MSS) (Figure 1). Approximately 15% of 
participants had NIPT due to abnormal ultrasound findings alone, 6% of participants had NIPT 
due to abnormal first trimester screens alone, and 2% were solely due to abnormal multiple 
marker screens (Figure 1). One participant had a NIPT ordered by parental request with no 
indication of increased risk for fetal aneuploidy. 
 
 
 
 
Figure 1. Clinical Indications for NIPT Utilization 
 
The average gestational age at which NIPT was drawn was 14.7 weeks (±4.55). A total of 
54 pregnancies (n=96, 27.87%) received a positive NIPT indicating an increased for trisomies 
21, 18, or 13; 45 (n=96, 47.87%) pregnancies were positive for trisomy 21, five pregnancies 
were positive for trisomy 18, and four pregnancies were positive for trisomy 13 (Figure 2). The 
majority of women who received positive trisomy 21 NIPT results were solely AMA or had 
multiple clinical indications (Figure 1). One of the pregnancies that was positive for trisomy 21 
also had an increased risk for Monosomy X as reported by NIPT. However, amniocentesis 
55%
15%
2%
6%
21%
1%
Clinical Indications for NIPT use 
AMA only US only MMS only
FTS only AMA/US/MMS parental request
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showed the presence of two X-chromosomes and trisomy 21 (47, XX, +21) in all cells analyzed 
by FISH and confirmed with karyotyping.   
Approximately 44% (n=42/96) of pregnancies received failed NIPT results. The test 
failure rate is estimated to be 1.62% (42/2589). NIPT failure due to inability of the sample to 
meet acceptable Quality Control (QC) standards set by each laboratory in order to perform 
analysis was reported for 24 pregnancies-23 singletons and one set of dichorionic/ diamniotic 
twins (Figure 2). A maternal metastatic malignancy was later detected at 22 weeks gestation for 
one singleton pregnancy whose reason for test failure was reported as “Did not meet QC 
threshold” at both attempts for NIPT analysis respectively drawn at 13 and 15 weeks of 
gestation. Failure due to “Specimen quantity not sufficient”- the extraction of an insufficient 
amount of cell-free fetal DNA due to a lowered amount of maternal serum sample submitted- 
was initially reported for three samples. Insufficient cell-free fetal DNA (listed as cffDNA in 
Figure 2) was reported as the reason for test failure in 10 samples. The reason for NIPT failure 
was not reported by testing laboratories for five failed results (Figure 2). One pregnancy that 
received an unspecified reason for failure was determined to be at a lowered gestational age than 
the laboratory’s minimal threshold. There was no statistically significant association between 
NIPT results received and the clinical indication for screening (p>0.120). 
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Figure 2. Number of Participants Who Received Each Type of NIPT Result
   After receiving an initial failed NIPT result, 26 participants chose to have their sample 
redrawn for NIPT analysis. All five of the participants who received a failed NIPT result due to 
unspecified reasons (n=5) elected to have a second NIPT sample drawn. Upon this second 
attempt, three of these participants obtained inconclusive sex chromosome aneuploidy panels, 
and were reported as low risk for trisomies 21,18, and 13. Two participants then received 
negative NIPT results (low risk for all aneuploidies) upon redraw. All three of the participants 
who received failed results due to “Specimen quantity not sufficient” chose to have their sample 
redrawn and received negative NIPT results. A total of thee three women elected to have their 
NIPT sample re-drawn after receiving an initial test failure due to insufficient fetal fraction 
(30%, n=10) obtained results upon their second draw. One participant was reported to be at an 
increased risk for Monosomy X, while the other two participants received negative results. A 
total of 15 participants who initially received a failure NIPT due to inability to meet the testing 
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laboratory’s QC threshold (62.5%, n=24) elected for a redraw. Six participants received a second 
NIPT failure upon re-draw, two of the failed results were due to insufficient cell-free fetal DNA, 
three were due to failure to meet the QC threshold, and one participant received a failed result 
due to lowered gestational age. The remaining nine participants received negative NIPT results 
upon their second blood draw. 
  A statistically significant correlation (p<0.001, α=0.05) between maternal body mass 
index (BMI) and the reported fetal fraction was observed within our cohort (Figure 3). 
Moreover, a statistical difference (p=0.0034) between the average BMI of participants who 
received positive NIPT results in comparison to participants who received failed NIPT results 
was observed (Figure 4). The median maternal BMI was the highest for participants whose 
NIPT initially failed due to “Specimen Quantity not Sufficient” errors. While, participants 
whose NIPT initially failed due to insufficient cell-free fetal DNA extracted from maternal serum 
samples had the lowest median BMI. The maternal BMIs for participants who received positive 
NIPT results are displayed in Appendix B.  
Figure 3. Relationship between Maternal Body Mass Index (BMI) and Fetal Fraction 
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Figure 4. Maternal BMI of Participants Who Received Positive or Failed NIPT Results 
    All NIPTs that were ordered through the Center for Medical Genetics and Genomics from 
January 1, 2014 to December 31, 2016 were sent to a total of seven clinical laboratories (Figure 
5, Appendix B). No statistically significant difference was observed between the number of 
positive or failed results reported by each laboratory (p>0.5) with the exclusion of Ariosa 
Diagnostic Inc-the most frequently used laboratory within this cohort (Figure 5).  
Figure 5. Commercial Laboratories Used for NIPT Analysis
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3.3.3 NIPT RESULTS AND DIAGNOSTIC TESTING 
Of the 96 pregnancies with an abnormal NIPT result, diagnostic testing was performed 
for 51 pregnancies (53.1%, n=96). Prenatal diagnostic testing (amniocentesis and chorionic villus 
sampling) was more commonly performed than postnatal diagnostic testing on cord or peripheral 
blood samples from neonates (Figure 6). Amniocentesis was the most frequently chosen type of 
diagnostic testing overall (Figure 6). Of the 42 participants who initially received a failed NIPT 
result, only eight women pursued diagnostic testing (19.0%, n=42). Diagnostic testing was not 
elected by any of the participants who received a failed result due to “Specimen Quantity not 
Sufficient” or for an unspecified reason (Figure 6). 
A total of five women (20.8%, n=24) who received a failed result due to failure to meet 
the laboratory’s QC threshold had diagnostic testing. One fetus (20%, n=5) was detected to have 
trisomy 13 due to a Robertsonian translocation (46,XX,+13, der(13;14)(q10;q10) in all analyzed 
cells. The other four fetuses (80%, n=5) who underwent diagnostic testing had normal 
karyotypes. Three women whose NIPT failed due to insufficient fetal fraction (30%, n=10) had 
diagnostic testing. Two of the pregnancies (66.7%, n=3) received normal karyotypes and one 
pregnancy was diagnosed with Klinefelter syndrome (47, XXY) (33.3%, n=3). Fetal aneuploidy 
was suspected in three additional pregnancies that received inconclusive sex chromosome 
aneuploidy panels upon repeat NIPT analysis after initially receiving a failed result due to 
reasons unspecified by the testing laboratory. None of these participants elected to have 
diagnostic testing. In addition, fetal aneuploidy was suspected in one pregnancy that initially 
received a failed NIPT result due to insufficient cffDNA but was predicted to be at an increased 
risk for Monosomy X upon NIPT re-draw and analysis. Amniocentesis was performed on the 
pregnancy and showed 46,XX in all cells analyzed. 
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Of the total of 45 participants whose initial NIPT was positive for trisomy 21, 38 (84%) 
chose to have diagnostic testing but results were obtained for only 37 pregnancies (Figure 6). 
Cytogenetic analysis was not able to be performed on the products of conception from one 
pregnancy due to lack of placental villi growth. No false positives were detected in this cohort, 
trisomy 21 was confirmed by diagnostic testing for all of the women with an increased risk for 
Trisomy 21 by NIPT (Figure 6, Table 6). For both of the dichorionic, diamniotic twin 
pregnancies that received an NIPT positive for trisomy 21, one fetus was detected to have 
trisomy 21. The positive predictive value for trisomy 21 was 100% (95% CI: 90.5-100) (Table 
7).  
Diagnostic testing was performed for three out of five participants whose initial NIPT 
was positive for trisomy 18. Diagnostic testing confirmed the presence of trisomy 18 in two 
fetuses, however a complex rearrangement resulting in partial monosomy of the p-arm of 
chromosome 18 was identified in the products of conception from the third pregnancy (Figure 6, 
Table 6). The positive predictive value for trisomy 18 in this cohort is 66.7% (95% CI: 9.4-99.2) 
(Table 7). 
The diagnostic testing results were known for two of the four women whose initial NIPT 
was positive for trisomy 13 (Figure 6). One of the results indicated a diagnosis of trisomy 13 and 
one result was a false positive based on chorionic villus sampling results (Figure 6, Table 6). 
Based on these results the positive predictive value for trisomy 13 within our cohort was 
determined to be 50% (95% CI 1.3-98.7) (Table 7).  
38 
Figure 6. Type of Diagnostic Testing Elected vs. NIPT Result
Table 6. Diagnostic Testing Results Based on NIPT 
Trisomy 
21 
Trisomy 
18 
Trisomy 
13 
47,XX,+21/18/13 19 1 0 
47,XY,+21/18/13 16 1 1 
unbalanced 
translocations 2 
46, XX 0 0 0 
46,XY 0 0 1 
complex 
structural defect 0 1 0 
Table 7. Positive Predictive Value for Each Trisomy
NIPT Result Number of 
positive 
results 
Number of positive results 
with diagnostic testing 
Number of 
true positives 
PPV (%) Confidence 
Interval 
Trisomy 21 45 37 37 100% 90.5-100 
Trisomy 18 5 3 2 66.7% 9.4-99.2 
Trisomy 13 3 2 1 50% 1.3-98.7 
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3.3.4 POSTNATAL FOLLOW-UP 
The postnatal outcomes were available for 92 out of 100 fetuses as depicted in Figure 7. 
Approximately half of the fetuses in our cohort were delivered (n=52, 57%) (Figure 8). The 
majority of fetuses who were delivered received an initial NIPT that was positive for trisomy 21 
or failed due to failure to meet the laboratory’s quality control threshold (Figure 8). Of the 
fetuses who were delivered (n=52), the average birth weight was 2.99 ±0.84 kg and the average 
birth length was 47.34 ±3.57 cm (Table 8).  The three pregnancies comprised of two singletons 
and one set of dichorionic/diamniotic twins that initially received failed NIPT results due to 
insufficient specimen quantity, were delivered. However, one singleton received an abnormal 
newborn screen indicating Bart’s hemoglobin and was subsequently diagnosed with Alpha 
thalassemia trait. All other newborns in our cohort with available newborn screening results 
received normal newborn screens.  
Figure 7. Birth Outcomes of Fetuses 
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Figure 8. Birth Outcomes of Fetuses based on Initial NIPT Result
Terminated abortions occurred for 16 (17.4%, n=92) fetuses with known birth outcomes 
(Figure 7). No fetuses who received failed results due to an unspecified reason or insufficient 
specimen quantity, were terminated (Figure 8). A total of 19 fetuses (20.7%, n=92) 
spontaneously aborted, the NIPT results of these pregnancies included trisomy 21, trisomy 18, 
failed due to lowered fetal fraction, failure to meet the quality control threshold and for an 
unspecified reason (Figure 8). Intrauterine fetal demises (5.43%, n=92) were reported for three 
fetuses who were positive for trisomy 21 by NIPT, one fetus whose NIPT was positive for 
trisomy 13, and one fetus whose initial NIPT failed due to failure to meet the quality control 
threshold (Figure 8).   
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Table 8. Neonatal Characteristics 
Birthweight (kg) Statistic 
Average Weight 2.99 
Standard Deviation 
Weight 
0.84 
Minimum 0.41 
Maximum 4.85 
Birth Length (cm) 
Average Length 47.34 
Standard Deviation 
Length 
3.57 
Minimum 41.00 
Maximum 53.00 
Postnatal diagnostic testing was elected for 21 fetuses (21%, n=100) with known 
diagnostic testing results. Cytogenetic studies were performed on a single peripheral blood 
sample (4.76%, n=21), 13 cord blood samples (61.9%, n=21), and seven products of conception 
(33.3%, n=21) (Appendix B). The fetus whom the peripheral blood sample was drawn from 
initially received a failed NIPT result due to the inability to meet the laboratory’s quality control 
threshold and, the karyotype was normal (46, XY). For the 13 fetuses who had cytogenetic 
studies performed on their cord blood samples, 12 had a NIPT that was positive for trisomy 21 
and confirmed on karyotype, one fetus who received a NIPT positive for trisomy 18 had an 
abnormal karyotype confirming the presence of trisomy 18 in all cells. Cytogenetic studies on 
the products of conception from seven pregnancies revealed one false positive NIPT result. One 
fetus received a positive NIPT for trisomy 18, however microarray analysis revealed a complex 
structural rearrangement leading to partial monosomy of 18p11.2 and chromosome material of 
unknown origin attached to the 18p11.2 segment. Trisomy 21 was confirmed by karyotype for all 
of the fetuses (n=6, 100%) who had a NIPT positive for trisomy 21 and submitted products of 
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conception for genetic analysis, with the exception of one fetal sample that was unable to grow 
under the cell culture conditions for karyotype analysis. 
3.4 DISCUSSION 
Due to its high sensitivity and specificity in combination with its non-invasive 
methodology, NIPT has become an increasingly popular pregnancy screening option since its 
launch in 2011. As the clinical uptake of NIPT continues to rise, the rate of invasive diagnostic 
procedures being performed has gradually declined18,20. However, since its release, a limited 
number of studies on the clinical use and validation of NIPT have been published19,51. Clinical 
assessment of NIPT outcome is essential for the provision of more accurate clinical correlation 
and interpretation of test results to then guide subsequent pregnancy care and management. The 
goal of this study was to quantitatively and qualitatively analyze our center’s experience with 
NIPT.  
3.4.1 COHORT DEMOGRAPHICS 
Our study identified participants from women who had NIPT through the Medical 
Genetics and Genomics department of Magee-Womens Hospital of UPMC from January 1, 2014 
to December 31, 2016. During this time period only women who were classified as high risk for 
fetal aneuploidy as specified by ACOG and the Society for Maternal-Fetal Medicine (SMFM) in 
their initial joint statement on NIPT were offered this screening11. The array of clinical 
indications for NIPT use in our cohort reflect this policy. A total of 53 pregnancies (55%, n=96) 
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in our cohort had a NIPT due to advanced maternal age (AMA) alone, six pregnancies (6%, 
n=96) had positive first trimester screening results, 14 pregnancies (15%, n=96) had abnormal 
ultrasound findings, two pregnancies had abnormal multiple marker screens (2%, n=96), and 20 
pregnancies (21%, n=96) had multiple clinical indications (Figure 1). A similar study conducted 
in 2013 by the Prenatal Diagnostics Unit at the University of North Carolina Chapel Hill also 
reported a similar distribution of clinical indications and a mean maternal age of 37± 7.4 
amongst its participants who had  NIPT in 201220. 
3.4.2 POSITIVE NIPT RESULTS 
Approximately 83.33% of the positive results (n=45/54) obtained by participants reported 
an increased risk for trisomy 21. Trisomy 21 has the highest incidence in liveborn infants 
compared to trisomies 13 and 183,23.  In addition, women of advanced maternal age are 
considered to be at an increased risk for fetal aneuploidy conditions, for example the chance for a 
37 year-old woman to have a child with a chromosome abnormality is approximately 1 in 6673,74. 
The average maternal age of participants in this study is advanced maternal age, 35.4 years ±5.88 
(Table 1).  
The positive predictive values for the common aneuploidies calculated for this cohort 
slightly varied from those reported by prior clinical studies of NIPT performance. Of the 45 
participants who received a NIPT positive for trisomy 21 and elected to have diagnostic testing, 
no false positives were detected and the positive predictive value was 100% (95% CI: 90.5-100). 
The positive predictive values for trisomy 21 reported by clinical studies ranged from 85-99.9% 
based on the sample size19,58,59. In a meta-analysis of NIPT clinical validation studies conducted 
in 2014 and a blinded, multicenter study performed at 35 international center, the calculated 
44 
positive predictive value for trisomy 21 was 99.0-100%52,59,75. There were no false positives 
detected for trisomy 21 in the 38 pregnancies that were included in the multicenter study 
conducted by Norton et al75. However, the overall false positive rate for trisomy 21 for the 
studies included in the meta-analysis was approximately 0.15%59. 
The calculated positive predictive values for trisomy 18 and 13 for this cohort were lower 
than those reported by prior studies. The positive predictive value for trisomy 18 was 66.7% 
(95% CI: 9.4-99.2%) and 50% (95% CI:1.3-98.7) for trisomy 13. The false positive rate for 
trisomy 18 was 33.3% (95% CI: 0.08-90.6) and 50% (95% CI: 1.26-98.7) for trisomy 13 within 
this cohort (Appendix B). However, these calculations were limited by the small sample sizes 
for trisomy 18 and trisomy 13 observed in this study. The positive predictive value for trisomy 
18 was  approximately 77% as reported by a large referral genetic diagnostic laboratory (n=106) 
and the false positive rate was 23%19. In an international study conducted in 2015, the positive 
predictive value for trisomy 18 was 74.3% for participants who received diagnostic testing 
(n=121)52. However in the meta-analysis of NIPT clinical validation studies the positive 
predictive value of trisomy 18 was 96.8% (95% CI 94.5–98.4)59.  
One of the participants who received a NIPT positive result for trisomy 18 was then 
detected to have a complex structural chromosome rearrangement through diagnostic testing. 
Microarray analysis of the products of conception from that pregnancy revealed 
46,XX,del(10)(?q24q25.2,add(18)(p11.2)ish 10q26.3(D10S2490x2), der(18)(18p11.32-
)(D18S552-) in all cells tested. FISH analysis showed evidence of an interstitial deletion on 
chromosome 10, and an abnormal chromosome 18 with monosomy of the 18p11.2-pter segment 
and unknown chromatin material at 18p11.2. However, NIPT has not been validated for the 
detection of complex chromosome structural rearrangements such as the one described5,51,76. A 
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retrospective analysis of 6,388 cases showed that 0.56% (n=258) of pregnancies that receive 
abnormal NIPT results had a pathogenic copy number variant revealed by diagnostic testing77. 
Moreover, no case reports of fetuses with this or structural rearrangements who received positive 
NIPT results have been described in the literature. 
3.4.3 FAILED NIPT RESULTS 
A number of research studies have shown that women who receive failed or inconclusive 
NIPT results are at an increased risk for fetal aneuploidy6,19,20,53,54,59,65. The ACMG encourages 
healthcare professionals to offer diagnostic testing and continued prenatal surveillance of 
pregnancies that received failed NIPT results5. The test failure rate of this cohort was 
approximately 1.62%, which is concordant with NIPT failure rates reported by other clinical 
studies who reported test failure rates of  1-2%19,20,54. The test failure rates for most commercial 
NIPT laboratories are not reported in their performance analytics or reported as >0.1%12–17. 
Fetal aneuploidy was confirmed or suspected in six pregnancies that initially received 
failed NIPT results. One pregnancy that received a failed result due to inability to meet the 
quality control threshold of the testing laboratory when the maternal serum sample was initially 
drawn at 12 weeks gestation, had an amniocentesis that detected trisomy 13 due to a 
Robertsonian translocation present in all analyzed cells. Throughout the pregnancy, the fetus 
displayed several features suggestive of trisomy 13 that were detected by ultrasound including 
but not limited to: cystic hygroma, alobar holoprosencephaly, Dandy-Walker malformation, and 
bilateral polydactyly of the hands, the pregnancy was terminated at 21 weeks78,79. Klinefelter 
syndrome (47, XXY) was detected by amniocentesis in another pregnancy that initially received 
a failed NIPT result due to insufficient cffDNA at 15 weeks gestation. The participant received a 
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second failed result upon sample re-draw and chose to have a third re-draw that resulted in a 
negative NIPT result with the fetal sex indicated as XY.  
One pregnancy that initially received a failed NIPT result due to insufficient cffDNA was 
indicated to be at an increased risk for Monosomy X upon sample re-draw and NIPT analysis. 
The participant chose to have an amniocentesis that showed a normal female karyotype (46, XX) 
and the fetus was delivered liveborn with no noted dysmorphic features. A possible right 
ventricular myocardium thickening versus thickening of the tricuspid valve was detected by 
ultrasound, although these findings were not observed in a subsequent fetal echocardiogram. No 
postnatal diagnostic testing was elected for this infant. In addition, three participants who 
received failed results due to a reason unspecified by the testing laboratory elected to repeat their 
NIPT and received negative NIPT results for trisomies 21, 18, and 13 but had inconclusive sex 
chromosome aneuploidy panels. No prenatal or post-natal diagnostic genetic testing was pursued 
for these pregnancies. One of the fetuses spontaneously aborted at 12 weeks gestation and two 
fetuses were delivered at full term with no fetal anomalies detected by ultrasound or postnatal 
evaluation within the first year of life. 
The discrepancies observed between the NIPT and diagnostic testing results and/or 
postnatal outcomes could be due to an array of potentially confounding factors. Errors in fetal 
aneuploidy detection by NIPT have been attributed- but not limited to: confined placental 
mosaicism, fetal somatic mosaicism, and/or technical limitations of NIPT, maternal copy number 
variants, a vanishing twin, and undiagnosed maternal malignancies53,54. Confined placental 
mosaicism is estimated to occur in 1-2% of all first trimester pregnancies that undergo CVS 
procedures, although the prevalence of confined placental mosaicism varies based on the exact 
condition80,81. Chromosomal mosaicism is independent of sex however sex chromosome 
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aneuploidies can generally be better tolerated by developing fetuses due to X-inactivation81. 
Also, somatic mosaicism is commonly observed in individuals with sex chromosome 
aneuploidies82,83.  
Several clinical studies have observed a higher incidence of false positive and false 
negative NIPT results for sex chromosome aneuploidy conditions10,19,59. Furthermore, the NIPT 
sensitivity and specificity reported by commercial testing companies for sex chromosome 
aneuploidy conditions are generally lower than those reported for trisomies 21,18, and 1312,13,17. 
Due to the prevalence of chromosomal mosaicism and numerous biological mechanisms 
underlying the development of sex chromosome aneuploidies it is recommended that infants who 
had prenatal diagnostic testing also follow-up with postnatal testing for more thorough 
assessment82,83. The absence of clinical features and/or a normal fetal karyotype created by 
prenatal diagnostic testing do not rule out the possibility of a sex chromosome aneuploidy82,84. 
Therefore, placental and somatic chromosomal mosaicism cannot be ruled out in the cases of 
Klinefelter syndrome and Monosomy X observed within our cohort. Moreover, due to the fact 
that diagnostic testing was declined by the three participants who received failed results then 
inconclusive sex chromosome aneuploidy panels, the possibility of a sex chromosome 
aneuploidy cannot be excluded in these cases. 
One risk factor for NIPT failure is higher maternal body mass index (BMI)5,54. A 
retrospective clinical assessment of NIPT outcomes in an Australian population showed that 
women who failed to receive a NIPT result had a higher mean maternal BMI in comparison to 
participants who received a result upon their first blood draw54. In particular, the participants 
who received a failed result due to a lowered fetal fraction extracted from their sample had a 
higher mean maternal BMI than all other participants54. The maternal mean BMI for participants 
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who received a failed NIPT due to a lowered fetal fraction (also referred to as insufficient cell-
free fetal DNA) was not the highest amongst the groups of women who received failed results in 
our cohort. The highest mean BMI was observed in the participants whose initial NIPT failed 
due to insufficient specimen quantity errors. However, a statistically significant difference 
between the mean maternal BMIs of the participants who received positive versus failed results 
was observed in this study (p=0.0034). Although, discrepancies between laboratory internal 
quality control and specimen quantity standards could confound results. 
Maternal use of anticoagulants during pregnancy has also been associated with NIPT 
failure due to low fetal fraction60,61. Specifically, use of low molecular weight heparin and/or 
Warfin have been associated with reduction in fetal fraction detected by NIPT analysis61. None 
of the participants (n=10) who received a failed result due to reduced fetal fraction were known 
to use either of those medications during or prior to their pregnancy.  
In vitro fertilization (IVF) and twin pregnancies have also been shown to be independent 
predictors of lowered fetal fraction85,86. IVF was used for three pregnancies within this cohort, 
two of these were singleton pregnancies while one case resulted in a twin gestation. One of the 
singleton pregnancies and the twin gestation received a positive NIPT result for trisomy 21. The 
presence of trisomy 21 was confirmed through diagnostic testing in the singleton pregnancy and 
one of the fetuses in the twin pregnancy that was conceived from maternal oocytes retrieved at 
age 36. The other singleton pregnancy conceived from a donor egg received a failed NIPT result 
due to inability to meet the laboratory’s quality control threshold at 12 weeks gestation. The 
participant chose to have their serum sample redrawn at 14 weeks gestation and received a 
negative result; the infant was liveborn with no complications or physical anomalies at 37 weeks. 
Four twin pregnancies were included in this cohort, two of the twin pregnancies received NIPT 
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results positive for trisomy 21, one of which was conceived through IVF. The other two twin 
pregnancies received failed NIPT results; IVF was not used for either of these pregnancies. 
Trisomy 21 was diagnosed in one fetus of the twin pair in both of the twin pregnancies that 
received positive NIPT results. The reported reasons for test failure in the two twin pregnancies 
that received failed NIPT results were insufficient specimen quantity and inability to meet the 
laboratory’s quality control threshold. Neither of the twin pregnancies that obtained failed NIPT 
results elected to undergo diagnostic testing; all four of these fetuses were delivered at full-term 
(37 weeks gestation or later). 
Occult maternal malignancies are a reported incidental finding of NIPT57. This screening 
test was derived from research on tumor DNA detection in the serum of cancer patients48,50. In a 
study conducted by Bianchi et al. seven pregnancies with subsequently diagnosed maternal 
cancers were detected by Illumina’s Verifi NIPT57. The NIPT reports for these seven pregnancies 
showed an increased risk for more than one aneuploidy and bioinformatics analysis of maternal 
serum samples revealed “nonspecific copy-number gains and losses across multiple 
chromosomes” suggestive of the presence of a tumor57.  One participant within our cohort was 
diagnosed with metastatic synchronous colon cancer at 22 weeks gestation, however this 
malignancy was not detected by NIPT. The initial NIPT drawn at 13 weeks gestation for this 
participant received a failed result due to inability to meet Ariosa Diagnostic’s quality control 
threshold, as did her subsequent sample drawn at 15 weeks of gestation and sent to Ariosa 
Diagnostics. No evidence of non-specific copy number gains or aneuploidy within the samples 
was reported. However, a rapidly enlarging adnexal mass, and enlarged left ovary (149 mm) with 
a multicystic appearance was seen on first trimester ultrasounds for the pregnancy. The fetus did 
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not have any detected physical abnormalities and delivered at 37 weeks of gestations with no 
complications.   
3.4.4 STUDY LIMITATIONS AND FUTURE DIRECTION 
This study has several limitations that can be addressed through future research studies. A 
limited sample size of 100 pregnancies that met the inclusion criteria were analyzed in this study. 
Due to the small sample size, results generated from this research should be carefully interpreted 
due to their limited generalizability. Moreover, subtle differences in the data may not have been 
observed or detected in our cohort due to the limited sample size. Future studies should increase 
the sample size to determine if there are associations between other risk factors such as maternal 
medication use and NIPT results.  
  Another limitation of this research was its retrospective design. Due to the fact that all 
data was collected at least 2 years after participants had their initial NIPT testing, some 
participants were lost to follow-up leading to an incomplete data set. In addition, there 
was limited or incomplete medical records available for a number of participants. Future 
research could include a prospective analysis to currently assess trends in NIPT utilization and 
outcomes to minimize loss to follow-up bias and increase the temporal relevancy of results. 
Thorough assessment of the clinical experience of genetic testing centers is essential for 
understanding the clinical utility and limitations of NIPT in order to increase the accuracy of 
information provided to patients during the informed consent process. Pregnancies that receive 
abnormal and failed NIPT results are at an increased risk for fetal aneuploidy and adverse prenatal 
outcomes. As a result, these pregnancies should receive increased surveillance and prenatal care 
to reduce maternal and fetal mortality and morbidity. Clinical correlation of NIPT results can help 
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to better direct the provision of appropriate healthcare services to patients, and identify current 
gaps in knowledge.  
3.5 CONCLUSION 
The launch of NIPT has made a significant impact on the field of prenatal genetics. The 
clinical adoption of NIPT continues to rapidly expand as more conditions and panels are offered 
by laboratories. However, research on the clinical outcomes and follow-up of pregnancies that 
received NIPT lags behind. Through our assessment of Magee-Womens Hospital of UPMC’s 
experience with NIPT, a test failure rate of 1.62% and positive predictive values of 100% (95% 
CI: 90.5-100) for trisomy 21, 66.7% (95% CI: 9.4-99.2) for trisomy 18, and 50% (95% CI: 1.3-
98.7) for trisomy 13 were obtained. Fetal aneuploidy was detected in two pregnancies that 
received failed NIPT results. These results can be used to provide more precise pre-test 
counseling in addition to genetic counseling for individuals interested in pursuing NIPT.  
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4.0 RESEARCH SIGNIFICANCE TO PUBLIC HEALTH AND GENETIC 
COUNSELING 
The core functions of public health are policy development, assessment, and assurance87. 
These functions provide the framework to achieve public health’s primary objective: the 
improvement of population health through prevention, protection, and promotion. A public 
health intervention that encompasses all three of these core functions is prenatal screening. 
Pregnancy screening enables healthcare professionals to assess the occurrence of health 
conditions such as aneuploidy within the population. Although there are known risk factors for 
fetal aneuploidy such as family history and maternal age, aneuploidy can also occur in 
pregnancies with no known risk factors3,39. It is estimated that 80% of children with trisomy 21 
are born to women under the age of 35 with no prior family history of trisomy 2139. By offering 
pregnancy screening healthcare providers can identify women within the general population who 
are at an increased risk to have a child with  a medical condition and/or experience adverse 
pregnancy outcomes. Through early detection provided by prenatal screening, pregnancy 
management plans, specialized medical care and services, in addition to psychological support 
can be provided to families, improving pregnancy outcomes. 
Initial pregnancy screening methods consisted of ultrasound and maternal serum 
screening tests. Using ultrasound imaging, physicians are able to visually assess the fetus for 
structural anomalies. However, due to technological limitations, positioning of the baby, and/or 
maternal weight, ultrasound is not able to detect all structural defects prenatally. Maternal serum 
screening tests were designed to increase prenatal detection rates for specific birth defects and 
genetic conditions such as Down syndrome and trisomy 18.  
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Since its launch, NIPT has quickly been incorporated into prenatal care and multiple 
professional organization including ACOG and NSGC have endorsed its use5,6,9,65. NIPT offers 
higher detection rates than its predecessors, and is able to detect trisomy 13 and sex chromosome 
aneuploidies in addition to trisomy 21 and 18 unlike any other prenatal genetic screening tests. 
However, the positive predictive value of NIPT results varies based on maternal age and the 
detected condition5,6,65,88. ACOG, NSGC, and ACMG maintain that healthcare professionals who 
order or discuss NIPTs with patients should determine the positive predictive values, false 
positive rates, and negative predictive values in order to accurately interpret their results for 
patients who choose to have screening5,6,9,65. Alternatively, healthcare providers can also refer 
their patients to discuss results with genetic specialists like genetic counselors5,6,9,65. According 
to NSGC’s 2016 Professional Status Survey, 43% of genetic counselors who counsel patients 
specialize in prenatal genetics and therefore, likely discuss NIPT with their patients on a regular 
basis89. 
In order for individuals to receive the most appropriate prenatal care and to make 
informed decisions regarding prenatal screening and pregnancy management decisions based on 
screening results, it is imperative that patients receive the most accurate information regarding 
NIPT. Through analysis of NIPT outcome, genetic counselors and other health care professionals 
can be equipped with information that has the potential to improve the informed consent process 
with their patients. For example, while multiple studies have shown that failure to receive a 
NIPT result is associated with an increased risk for adverse pregnancy outcomes, many of the 
biological mechanisms that contribute to these failures remain unknown22,54,56,60. This study 
showed that fetal aneuploidy was later confirmed in two pregnancies that initially received a 
failed NIPT result, one of which resulted in a spontaneous abortion. Follow-up of the clinical 
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outcomes of abnormal and failed NIPT results can aid healthcare professionals in providing 
families with more precise pre- and post-test counseling to identify more cases of fetal 
aneuploidy and improve pregnancy outcomes.   
55 
APPENDIX A: INTERNATIONAL REVIEW BOARD APPROVAL 
PITT SEAL  
University of 
Pittsburgh
Institutional Review Board 
3500 Fifth 
Avenue 
Pittsburgh, PA 15213 
(412) 383-1480 
(412) 383-1508 (fax) 
http://www.irb.pitt.edu
Memorandum 
To: Aleksandar Rajkovic 
From: IRB Office 
Date: 1/2/2018  
IRB#: PRO17100348 
Subject
: 
Non-invasive prenatal testing performance in 
the academic setting 
The University of Pittsburgh Institutional Review Board reviewed and approved 
the above referenced study by the expedited review procedure authorized under 45 CFR 
46.110 and 21 CFR 56.110.  Your research study was approved under: 
45 CFR 46.110.(5) 
The IRB has approved a waiver of informed consent/HIPAA authorization to 
access, record and use protected patient health information/patient medical record 
information. 
This study has been approved under 45 CFR 46.404 for the inclusion of children. 
The risk level designation is Minimal Risk. 
56 
Approval 
Date: 1/2/2018 
Expiration 
Date: 1/1/2019 
For studies being conducted in UPMC facilities, no clinical activities can be 
undertaken by investigators until they have received approval from the UPMC Fiscal 
Review Office. 
Please note that it is the investigator’s responsibility to report to the IRB any 
unanticipated problems involving risks to subjects or others [see 45 CFR 46.103(b)(5) 
and 21 CFR 56.108(b)]. Refer to the IRB Policy and Procedure Manual regarding the 
reporting requirements for unanticipated problems which include, but are not limited 
to, adverse events.  If you have any questions about this process, please contact the 
Adverse Events Coordinator at 412-383-1480. 
The protocol and consent forms, along with a brief progress report must be 
resubmitted at least one month prior to the renewal date noted above as required by 
FWA00006790 (University of Pittsburgh), FWA00006735 (University of Pittsburgh 
Medical Center), FWA00000600 (Children’s Hospital of Pittsburgh), FWA00003567 
(Magee-Womens Health Corporation), FWA00003338 (University of Pittsburgh 
Medical Center Cancer Institute). 
Please be advised that your research study may be audited periodically by 
the University of Pittsburgh Research Conduct and Compliance Office. 
57 
APPENDIX B: SUPPLEMENTARY TABLES AND FIGURES 
Table 9. NIPT results vs. Clinical Indication for NIPT Utilization
NIPT Result AMA US FTS MMS AMA/US/MMS/FTS Parental Request 
Trisomy 21 17 8 3 1 16 
1 
Trisomy 18 1 0 1 1 2 0 
Trisomy 13 2 1 0 0 1 0 
failed 32 5 2 0 2 0 
TOTAL 53 14 6 2 20 1 
Table 10. Labs used for Non-invasive Prenatal Testing per Year
Year Sequenom Ariosa Integrated Quest Illumina Natera Verinata 
2014 1 1 8 9 4 0 3 
2015 0 18 0 12 0 1 0 
2016 0 54 0 0 0 3 0 
Total 1 73 8 21 4 4 3 
Figure 9. Maternal Body Mass Index vs. Positive NIPT Result: 
* Var 8= trisomy 18
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Table 11. Presence of US Findings by NIPT Result 
NIPT Result no US findings US findings 
Trisomy 21 8 37 
Trisomy 18 0 5 
Trisomy 13 2 2 
Failed: Specimen 
quantity not sufficient 0 3 
Failed: Did not meet QC 
threshold 6 18 
Failed: Unspecified 
Reason 5 1 
Failed: Insufficient fetal 
cffDNA 5 5 
Table 12. NIPT Results Received From Each Laboratory 
Positive results Failed Results 
Lab Trisomy 
21 
Trisomy 
18 
Trisomy 
13 
QC 
threshold 
quantity 
not 
sufficient 
cffDNA Reason 
Unspecified 
Ariosa 26 1 4 21 2 4 5 
Quest 12 1 0 3 0 4 0 
Natera 0 0 0 0 0 1 0 
Illumina 3 0 0 0 0 0 0 
Integrated 3 1 0 0 0 1 1 
Verinata 1 2 0 0 0 0 0 
Sequenom 0 0 0 0 1 0 0 
Table 13. False Positive Rates of NIPT Results 
Aneuploidy False Positive 
Rate 
Confidence Interval (95%) 
Trisomy 21 0% N/A 
Trisomy 18 33.3% 0.08-90.6 
Trisomy 13 50% 1.26-98.7 
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